LGMHD Quote, Financials, Valuation and Earnings

Crona has a net margin of -- compared to Veri Medtech Holdings's net margin of --. Veri Medtech Holdings's return on equity of -- beat Crona's return on equity of --.

Veri Medtech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Crona has an analysts' consensus of -- which suggests that it could fall by --. Given that Veri Medtech Holdings has higher upside potential than Crona, analysts believe Veri Medtech Holdings is more attractive than Crona.

Veri Medtech Holdings has a beta of 0.547, which suggesting that the stock is 45.273% less volatile than S&P 500. In comparison Crona has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veri Medtech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Crona offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veri Medtech Holdings pays -- of its earnings as a dividend. Crona pays out -- of its earnings as a dividend.

Veri Medtech Holdings quarterly revenues are --, which are smaller than Crona quarterly revenues of --. Veri Medtech Holdings's net income of -- is lower than Crona's net income of -$16.2K. Notably, Veri Medtech Holdings's price-to-earnings ratio is -- while Crona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veri Medtech Holdings is -- versus -- for Crona. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Communications Holdings has a net margin of -- compared to Veri Medtech Holdings's net margin of -24.54%. Veri Medtech Holdings's return on equity of -- beat Cogent Communications Holdings's return on equity of 8.6%.

Veri Medtech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Cogent Communications Holdings has an analysts' consensus of $82.09 which suggests that it could grow by 13.25%. Given that Cogent Communications Holdings has higher upside potential than Veri Medtech Holdings, analysts believe Cogent Communications Holdings is more attractive than Veri Medtech Holdings.

Veri Medtech Holdings has a beta of 0.547, which suggesting that the stock is 45.273% less volatile than S&P 500. In comparison Cogent Communications Holdings has a beta of 0.403, suggesting its less volatile than the S&P 500 by 59.745%.

Veri Medtech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Communications Holdings offers a yield of 5.41% to investors and pays a quarterly dividend of $1.00 per share. Veri Medtech Holdings pays -- of its earnings as a dividend. Cogent Communications Holdings pays out 14.27% of its earnings as a dividend. Cogent Communications Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veri Medtech Holdings quarterly revenues are --, which are smaller than Cogent Communications Holdings quarterly revenues of $257.2M. Veri Medtech Holdings's net income of -- is lower than Cogent Communications Holdings's net income of -$63.1M. Notably, Veri Medtech Holdings's price-to-earnings ratio is -- while Cogent Communications Holdings's PE ratio is 92.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veri Medtech Holdings is -- versus 3.28x for Cogent Communications Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Kartoon Studios has a net margin of -- compared to Veri Medtech Holdings's net margin of -23.62%. Veri Medtech Holdings's return on equity of -- beat Kartoon Studios's return on equity of -77.33%.

Veri Medtech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Kartoon Studios has an analysts' consensus of -- which suggests that it could grow by 7553.06%. Given that Kartoon Studios has higher upside potential than Veri Medtech Holdings, analysts believe Kartoon Studios is more attractive than Veri Medtech Holdings.

Veri Medtech Holdings has a beta of 0.547, which suggesting that the stock is 45.273% less volatile than S&P 500. In comparison Kartoon Studios has a beta of 2.784, suggesting its more volatile than the S&P 500 by 178.37%.

Veri Medtech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kartoon Studios offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veri Medtech Holdings pays -- of its earnings as a dividend. Kartoon Studios pays out -- of its earnings as a dividend.

Veri Medtech Holdings quarterly revenues are --, which are smaller than Kartoon Studios quarterly revenues of $8.7M. Veri Medtech Holdings's net income of -- is lower than Kartoon Studios's net income of -$2.1M. Notably, Veri Medtech Holdings's price-to-earnings ratio is -- while Kartoon Studios's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veri Medtech Holdings is -- versus 0.68x for Kartoon Studios. Usually stocks with elevated PS ratios are considered overvalued.

Zedge has a net margin of -- compared to Veri Medtech Holdings's net margin of -4.71%. Veri Medtech Holdings's return on equity of -- beat Zedge's return on equity of -29.39%.

Veri Medtech Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Zedge has an analysts' consensus of $4.00 which suggests that it could grow by 53.85%. Given that Zedge has higher upside potential than Veri Medtech Holdings, analysts believe Zedge is more attractive than Veri Medtech Holdings.

Veri Medtech Holdings has a beta of 0.547, which suggesting that the stock is 45.273% less volatile than S&P 500. In comparison Zedge has a beta of 1.244, suggesting its more volatile than the S&P 500 by 24.413%.

Veri Medtech Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zedge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veri Medtech Holdings pays -- of its earnings as a dividend. Zedge pays out -- of its earnings as a dividend.

Veri Medtech Holdings quarterly revenues are --, which are smaller than Zedge quarterly revenues of $7.2M. Veri Medtech Holdings's net income of -- is lower than Zedge's net income of -$339K. Notably, Veri Medtech Holdings's price-to-earnings ratio is -- while Zedge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veri Medtech Holdings is -- versus 1.22x for Zedge. Usually stocks with elevated PS ratios are considered overvalued.